A Phase 3 Study of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis

PHASE3CompletedINTERVENTIONAL

Enrollment

251

Participants

Timeline

Start Date

April 17, 2012

Primary Completion Date

October 5, 2012

Study Completion Date

October 5, 2012

Conditions

Bacterial Vaginosis

Interventions

DRUG

1% SPL7013 Gel

Vaginal gel, daily for 7 days

DRUG

Placebo

Vaginal gel, daily for 7 days

All Listed Sponsors

lead

Starpharma Pty Ltd

INDUSTRY

NCT01577537 - A Phase 3 Study of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis | Biotech Hunter | Biotech Hunter